NBP — NovaBridge Biosciences Share News
0.000.00%
Last trade - 00:00- $158.92m
- -$31.93m
Brief: I-Mab Transitions To NovaBridge Biosciences With Trading Effective October 30, 2025
U.S. RESEARCH ROUNDUP- Citigroup, eBay, Morgan Stanley
I-Mab tumbles on China drug report, analyst calls selloff overreaction
Brief: I-Mab Announces Acceleration Of Givastomig Investment And Leadership Appointments
Brief: I-Mab Wei Fu, I-Mab’S Chairman Of Board, Appointed As Executive Chairman
Brief: I-Mab Announces Pricing Of $65 Million Underwritten Offering Of American Depositary Shares
Brief: I-Mab Strengthens Givastomig Intellectual Property Portfolio Through Acquisition Of Bridge Health
I-Mab reports results for the quarter ended March 31 - Earnings Summary
Brief: I-Mab Reports First Quarter 2025 Financial Results
Brief: I-Mab Announces Givastomig Abstract Accepted For Oral Presentation At ESMO GI 2025
I-Mab expected to post a loss of 11 cents a share - Earnings Preview
Brief: I-Mab Reports Full Year 2024 Financial Results
I-Mab expected to post a loss of 11 cents a share - Earnings Preview
Brief: I-Mab gets Nasdaq notice regarding minimum bid price requirement
I-Mab expected to post a loss of 11 cents a share - Earnings Preview
I-Mab expected to post a loss of 11 cents a share - Earnings Preview
I-Mab expected to post a loss of 11 cents a share - Earnings Preview
Brief: I-Mab Announces Accelerated Givastomig Phase 1B Study Progress
U.S. RESEARCH ROUNDUP-Antero Resources, IGM Biosciences, Lennar